Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2024-09-25 Director's Dealing
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. This type of filing is specifically used to report insider transactions or changes in share ownership by directors and major shareholders. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-09-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider shareholding changes, which falls under the 'Director's Dealing' category (DIRS) as it details the share ownership status and changes for a major shareholder (Gem & Company) of the issuer (GemVax & Kael).
2024-09-25 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule report). It details changes in share ownership, including major shareholding notifications, special relationships, and contractual arrangements like pledges and loans. This fits the 'Major Shareholding Notification' category.
2024-09-25 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Contract for Collateral Provision involving a Change in the Largest Shareholder'. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting changes in collateralized shares held by major shareholders. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-09-25 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose, and contact information for the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like M&A or dividend announcements, it is classified as a general regulatory filing/announcement.
2024-09-24 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Contract for Stock Collateralization involving a Change in Largest Shareholder'. This type of filing is a standard regulatory disclosure required by the Korea Exchange (KRX) when major shareholders pledge their shares as collateral for loans. It does not fit into categories like Annual Reports, Earnings Releases, or M&A. Since it is a specific regulatory disclosure regarding capital structure and share pledging, it falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for miscellaneous regulatory announcements.
2024-09-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.